Literature DB >> 17597999

Update on antithrombin I (fibrin).

Michael W Mosesson1.   

Abstract

Antithrombin I (fibrin) is an important inhibitor of thrombin generation that functions by sequestering thrombin in the forming fibrin clot, and also by reducing the catalytic activity of fibrinbound thrombin. Thrombin binding to fibrin takes place at two classes of non-substrate sites: 1) in the fibrin E domain (two per molecule) through interaction with thrombin exosite 1; 2) at a single site on each gamma' chain through interaction with thrombin exosite 2. The latter reaction results in allosteric changes that down-regulate thrombin catalytic activity. Antithrombin I deficiency (afibrinogenemia), defective thrombin binding to fibrin (antithrombin I defect) found in certain dysfibrinogenemias (e.g. fibrinogen Naples 1), or a reduced plasma gamma' chain content (reduced antithrombin I activity), predispose to intravascular thrombosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17597999

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  28 in total

1.  High mortality associated with intracardiac and intrapulmonary thromboses after cardiopulmonary bypass.

Authors:  Satoru Ogawa; James E Richardson; Tetsuro Sakai; Masahiro Ide; Kenichi A Tanaka
Journal:  J Anesth       Date:  2011-10-19       Impact factor: 2.078

2.  Prospective study of γ' fibrinogen and incident venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE).

Authors:  Aaron R Folsom; Weihong Tang; Kristen M George; Susan R Heckbert; Richard F MacLehose; Mary Cushman; James S Pankow
Journal:  Thromb Res       Date:  2016-01-12       Impact factor: 3.944

3.  Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery.

Authors:  C Solomon; U Pichlmaier; H Schoechl; C Hagl; K Raymondos; D Scheinichen; W Koppert; N Rahe-Meyer
Journal:  Br J Anaesth       Date:  2010-03-26       Impact factor: 9.166

Review 4.  Thrombosis in Inherited Fibrinogen Disorders.

Authors:  Wolfgang Korte; Man-Chiu Poon; Alfonso Iorio; Michael Makris
Journal:  Transfus Med Hemother       Date:  2017-03-14       Impact factor: 3.747

5.  Specific effects of fibrinogen and the γA and γ'-chain fibrinogen variants on angiogenesis and wound healing.

Authors:  Elim Y L Cheung; Ester M Weijers; Bastiaan Tuk; Reinilde Scheffer; Frank W Leebeek; Johan W van Neck; Pieter Koolwijk; Moniek P M de Maat
Journal:  Tissue Eng Part A       Date:  2014-08-05       Impact factor: 3.845

6.  Primetime for γ'.

Authors:  David H Farrell
Journal:  Blood       Date:  2014-08-28       Impact factor: 22.113

Review 7.  What Is the Biological and Clinical Relevance of Fibrin?

Authors:  Rustem I Litvinov; John W Weisel
Journal:  Semin Thromb Hemost       Date:  2016-04-07       Impact factor: 4.180

Review 8.  Fibrin Formation, Structure and Properties.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Subcell Biochem       Date:  2017

9.  Batroxobin binds fibrin with higher affinity and promotes clot expansion to a greater extent than thrombin.

Authors:  Trang T Vu; Alan R Stafford; Beverly A Leslie; Paul Y Kim; James C Fredenburgh; Jeffrey I Weitz
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

10.  Lack of association of plasma gamma prime (γ') fibrinogen with incident cardiovascular disease.

Authors:  Duke Appiah; Susan R Heckbert; Mary Cushman; Bruce M Psaty; Aaron R Folsom
Journal:  Thromb Res       Date:  2016-04-28       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.